Literature DB >> 16358336

Motor neuron disease in a patient with a mitochondrial tRNAIle mutation.

Gillian M Borthwick1, Robert W Taylor, Timothy J Walls, Kasia Tonska, Geoffrey A Taylor, Pamela J Shaw, Paul G Ince, Douglass M Turnbull.   

Abstract

OBJECTIVE: Motor neuron disease (MND) is a common neurodegenerative condition for which the underlying cause is uncertain in many patients. We identified a patient with clinical features suggestive of MND but additional cardiac and metabolic symptoms. We wished to determine if the clinical features were due to a mitochondrial DNA mutation.
METHODS: The brain and spinal cord were studied using neuropathological techniques and agenetic defect investigated in individual neurons.
RESULTS: There were atypical neuropathological features and genetic studies identified a pathogenic, heteroplasmic mitochondria tRNA(Ile) (4274T>C) mutation.
INTERPRETATION: This case adds to the phenotypic variation seen in mitochondrial DNA disease but also highlights the potential role of mitochondrial dysfunction in the cause of MND.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16358336     DOI: 10.1002/ana.20758

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  23 in total

Review 1.  Non-coding RNAs in the nervous system.

Authors:  Mark F Mehler; John S Mattick
Journal:  J Physiol       Date:  2006-06-29       Impact factor: 5.182

2.  Investigation of the mitochondrial genome in patients with atypical motor neuron disease.

Authors:  Catherine Phoenix; Geoffrey A Taylor; Judith Hartley; Hannah Nixon; Paul G Ince; Pamela J Shaw; Douglass M Turnbull; Robert W Taylor
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

Review 3.  The clinical maze of mitochondrial neurology.

Authors:  Salvatore DiMauro; Eric A Schon; Valerio Carelli; Michio Hirano
Journal:  Nat Rev Neurol       Date:  2013-07-09       Impact factor: 42.937

Review 4.  The role of mitochondria in neurodegenerative diseases.

Authors:  Massimiliano Filosto; Mauro Scarpelli; Maria Sofia Cotelli; Valentina Vielmi; Alice Todeschini; Valeria Gregorelli; Paola Tonin; Giuliano Tomelleri; Alessandro Padovani
Journal:  J Neurol       Date:  2011-05-22       Impact factor: 4.849

Review 5.  Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis.

Authors:  Wenzhi Tan; Piera Pasinelli; Davide Trotti
Journal:  Biochim Biophys Acta       Date:  2014-02-22

Review 6.  Mitochondrial genome changes and neurodegenerative diseases.

Authors:  Milena Pinto; Carlos T Moraes
Journal:  Biochim Biophys Acta       Date:  2013-11-16

Review 7.  Targeting angiogenin in therapy of amyotropic lateral sclerosis.

Authors:  Hiroko Kishikawa; David Wu; Guo-fu Hu
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

8.  Dysregulated A to I RNA editing and non-coding RNAs in neurodegeneration.

Authors:  Minati Singh
Journal:  Front Genet       Date:  2013-01-22       Impact factor: 4.599

Review 9.  The mitochondrial permeability transition pore: a molecular target for amyotrophic lateral sclerosis therapy.

Authors:  Lee J Martin
Journal:  Biochim Biophys Acta       Date:  2009-08-03

10.  Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS).

Authors:  Laura E Cox; Laura Ferraiuolo; Emily F Goodall; Paul R Heath; Adrian Higginbottom; Heather Mortiboys; Hannah C Hollinger; Judith A Hartley; Alice Brockington; Christine E Burness; Karen E Morrison; Stephen B Wharton; Andrew J Grierson; Paul G Ince; Janine Kirby; Pamela J Shaw
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.